Article
Oncology
Spencer C. Wei, Wouter C. Meijers, Margaret L. Axelrod, Nana-Ama A. S. Anang, Elles M. Screever, Elizabeth C. Wescott, Douglas B. Johnson, Elizabeth Whitley, Lorenz Lehmann, Pierre-Yves Courand, James J. Mancuso, Lauren E. Himmel, Benedicte Lebrun-Vignes, Matthew J. Wleklinski, Bjorn C. Knollmann, Jayashree Srinivasan, Yu Li, Oluwatomisin T. Atolagbe, Xiayu Rao, Yang Zhao, Jing Wang, Lauren I. R. Ehrlich, Padmanee Sharma, Joe-Elie Salem, Justin M. Balko, Javid J. Moslehi, James P. Allison
Summary: This study presents a robust preclinical model of ICI-associated myocarditis that recapitulates the clinical syndrome. Using this model, researchers demonstrate that CTLA4 and PD-1 (ICI targets) functionally interact in the development of myocarditis, and intervention with CTLA4-Ig (abatacept) attenuates myocarditis, providing mechanistic rationale and preclinical support for therapeutic clinical studies.
Article
Medicine, General & Internal
Tomoka Nishimura, Kiichiro Ninomiya, Mitsutaka Nakashima, Satoshi Akagi, Tadahiro Kuribayashi, Hisao Higo, Katsuyuki Hotta, Yoshinobu Maeda, Hiroshi Ito, Katsuyuki Kiura
Summary: A 59-year-old man with a high antinuclear antibody level developed fulminant myocarditis as an immune-related adverse event after receiving nivolumab, ipilimumab, and chemotherapy for lung cancer. Despite high-dose corticosteroid treatment, his cardiac function rapidly deteriorated, leading to death on the fifth day after admission. Further investigation is needed to establish treatment strategies for fulminant myocarditis as an immune-related adverse event.
Article
Immunology
Alberto Torres-Zurita, Lucia Vazquez-Montero, Laura Gallego-Lopez, Maria Dolores Mediano-Rambla, Luis de la Cruz-Merino
Summary: Immune checkpoint inhibitors have become an important treatment for many tumors, but they are also associated with several new side effects. We present a case of a 41-year-old male patient with advanced hepatocellular carcinoma who developed adverse reactions, including lymphadenopathy and anterior uveitis, after receiving combination therapy with nivolumab and ipilimumab. The diagnosis was confirmed to be a sarcoidosis-like reaction induced by immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Raymond A. Isidro, Alex B. Ruan, Swetha Gannarapu, Dhanya Raj, Osama Rahma, Shilpa Grover, Amitabh Srivastava
Summary: This study evaluated the prevalence of different histopathological patterns of injury in patients with immune checkpoint inhibitor colitis. It found that patients on ipilimumab were more likely to have diffuse active colitis, while patients on nivolumab and pembrolizumab were more likely to have lymphocytic colitis and collagenous colitis. Additionally, chronic active colitis was most frequent in nivolumab patients who had received more doses and had been on treatment longer.
Article
Immunology
Canhua Luo, Huangwei Chen, Huihuan Wu, Yongjia Liu, Guoyin Li, Weijian Lun
Summary: This article presents a case of colitis induced by Toripalimab in a patient with advanced nasopharyngeal carcinoma. The patient's symptoms were accompanied by inflammatory manifestations evident in colonoscopy and pathology results, which revealed cytomegalovirus (CMV) infection. Treatment with ganciclovir and steroids resulted in symptom relief and mucosal healing. The findings highlight the association between irColitis caused by Toripalimab and CMV infection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Jonathan W. Lo, Domenico Cozzetto, James L. Alexander, Nathan P. Danckert, Matthew Madgwick, Naomi Knox, Jillian Yong Xin Sieh, Marton Olbei, Zhigang Liu, Hajir Ibraheim, Jesus Miguens Blanco, Hiromi Kudo, Rocio Castro Seoane, Lucia A. Possamai, Robert Goldin, Julian Marchesi, Tamas Korcsmaros, Graham M. Lord, Nick Powell
Summary: Immune checkpoint inhibitors (CPIs) are a new cancer treatment that can potentially cure previously untreatable diseases. However, they can also cause off-target immune-mediated tissue injury. Researchers found that CPI-colitis in mice depends on the composition of the intestinal microbiota and the expression of certain immune molecules. Targeting these factors may hold the key to reversing CPI-colitis.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Armin Gerbitz, Regina Gary, Michael Aigner, Andreas Moosmann, Anita Kremer, Christoph Schmid, Klaus Hirschbuehl, Eva Wagner, Beate Hauptrock, Daniel Teschner, Wolf Roesler, Bernd Spriewald, Johanna Tischer, Stephanie Moi, Heidi Balzer, Stefanie Schaffer, Judith Bausenwein, Anja Wagner, Franziska Schmidt, Jens Brestrich, Barbara Ullrich, Stefanie Maas, Susanne Herold, Julian Strobel, Robert Zimmermann, Volker Weisbach, Leo Hansmann, Fernanda Lammoglia-Cobo, Mats Remberger, Matthias Stelljes, Francis Ayuk, Robert Zeiser, Andreas Mackensen
Summary: The study results showed that the use of CMV and EBV specific T cells derived from allogeneic stem cell grafts can safely prevent and preemptively treat reactivation of the viruses without inducing acute graft versus host disease.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Despina Michailidou, Ali Raza Khaki, Maria Pia Morelli, Leonidas Diamantopoulos, Namrata Singh, Petros Grivas
Summary: This study investigated the association between immune related adverse events (irAEs) and biomarkers in cancer patients receiving immune checkpoint inhibitors, identifying several risk factors. Patients with specific laboratory markers and clinical features had an increased risk of irAEs while lower NLR, MLR, and PLR were associated with longer overall survival. These findings suggest that baseline measurements and autoimmune history play a role in predicting irAEs and outcomes.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
S. Jennifer Wang, Stephanie K. Dougan, Michael Dougan
Summary: Immunotherapy has revolutionized cancer treatment in the past decade, with inhibitors of immune checkpoint proteins showing promising results. However, inflammatory toxicities can limit the effectiveness of these treatments and pose life-threatening risks. Advances in understanding the mechanisms and management of these toxicities are crucial for optimizing therapies and minimizing interference with antitumor immunity.
Review
Immunology
Jee Hye Kang, Jeffrey A. Bluestone, Arabella Young
Summary: Cancer immunotherapies can activate immune responses against tumors but may also lead to immune-related adverse events, with cytokine production playing a key role. Therapeutic agents that inhibit cytokine activity can reduce the severity of these adverse events.
TRENDS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Matteo S. Carlino, James Larkin, Georgina V. Long
Summary: Immune checkpoint inhibitors, particularly anti-CTLA4 and anti-PD-1 antibodies, have significantly improved the management of various cancers, with impressive outcomes in advanced melanoma. However, they can also lead to autoimmune toxicities, which require prompt recognition and management.
Article
Oncology
Anna Carbo-Bague, Roser Fort-Culillas, Helena Pla-Juher, Jordi Rubio-Casadevall
Summary: Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event, with little known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. In this case, the patient did not have a recurrence of AIHA after remission with steroids, and remained stable after switching to ipilimumab (anti-CTLA4).
CASE REPORTS IN ONCOLOGY
(2021)
Review
Rheumatology
Foteini Angelopoulou, Dimitrios Bogdanos, Theodoros Dimitroulas, Lazaros Sakkas, Dimitrios Daoussis
Summary: Immune checkpoint inhibitors (ICI) are associated with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. Studies show that 1 out of 15 patients treated with ICI will develop musculoskeletal Ir-AE, with most cases having mild/moderate severity of symptoms.
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Laine Lyles, Reagan Farmer, Marwan Abougergi
Summary: With the increasing use of immune checkpoint inhibitors, there is a rising incidence of medication-induced autoimmune hepatitis, as seen in this case of a 35-year-old woman with renal cell carcinoma.
ACG CASE REPORTS JOURNAL
(2023)
Article
Medicine, General & Internal
Ashish Sethi, Alexander Helfand, Lame Balikani, Mark Bunker, Gene Finley
Summary: ICIs have revolutionized the management of solid tumors, but they may lead to immune-related adverse effects like celiac disease which can have negative outcomes during cancer treatment.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Letter
Oncology
Michael Constantin Kirchberger, Bastian Schilling, Sebastian Haferkamp, Anja Bosserhoff, Gerold Schuler, Lucie Heinzerling
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2018)
Article
Oncology
Michael Constantin Kirchberger, Selma Ugurel, Johanna Mangana, Markus Valentin Heppt, Thomas Kurt Eigentler, Carola Berking, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie Heinzerling
EUROPEAN JOURNAL OF CANCER
(2018)
Article
Biochemistry & Molecular Biology
Jan Doerrie, Lek Babalija, Stefanie Hoyer, Kerstin F. Gerer, Gerold Schuler, Lucie Heinzerling, Niels Schaft
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2018)
Article
Oncology
Azadeh Tajmir-Riahi, Tanja Bergmann, Michael Schmid, Abbas Agaimy, Gerold Schuler, Lucie Heinzerling
JOURNAL OF IMMUNOTHERAPY
(2018)
Meeting Abstract
Cardiac & Cardiovascular Systems
Syed Mahmood, Michael G. Fradley, Justine V. Cohen, Anju Nohria, Kerry L. Reynolds, Lucie M. Heinzerling, Ryan J. Sullivan, Rongras Damrongwatanasuk, Carol Chen, Dipti Gupta, Michael C. Kirchberger, Javid Moslehi, Sachin Shah, Sarju Ganatra, Paaladinesh Thavendiranathan, Donald P. Lawrence, John D. Groarke, Tomas G. Neilan
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2018)
Article
Multidisciplinary Sciences
Matthias Augustin, Christine Blome, Andrea Forschner, Ralf Gutzmer, Axel Hauschild, Lucie Heinzerling, Elisabeth Livingstone, Carmen Loquai, Dirk Schadendorf, Jochen Utikal, Tobias Wagner, Sophia Wilden, Katharina C. Kaehler
Article
Oncology
Stefan Schliep, Abbas Agaimy, Alexander Cavallaro, Franklin Kiesewetter, Gerold Schuler, Lucie Heinzerling
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2018)
Article
Oncology
Tobias Wagner, Matthias Augustin, Christine Blome, Andrea Forschner, Claus Garbe, Ralf Gutzmer, Axel Hauschild, Lucie Heinzerling, Elisabeth Livingstone, Carmen Loquai, Dirk Schadendorf, Patrick Terheyden, Tina Mueller-Brenne, Katharina C. Kaehler
EUROPEAN JOURNAL OF CANCER CARE
(2018)
Article
Oncology
Alvaro Moreira, Stefanie Gross, Michael Constantin Kirchberger, Michael Erdmann, Gerold Schuler, Lucie Heinzerling
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Oncology
Alvaro Moreira, Carmen Loquai, Claudia Pfoefer, Katharina C. Kaehler, Samuel Knauss, Markus V. Heppt, Ralf Gutzmer, Florentia Dimitriou, Friedegund Meier, Heidrun Mitzel-Rink, Gerold Schuler, Patrick Terheyden, Kai-Martin Thoms, Matthias Tuerk, Reinhard Dummer, Lisa Zimmer, Rolf Schroeder, Lucie Heinzerling
EUROPEAN JOURNAL OF CANCER
(2019)
Article
Dermatology
Marie K. Priebe, Nadin Dewert, Katharina Amschler, Luise Erpenbeck, Lucie Heinzerling, Michael P. Schoen, Cornelia S. Seitz, Verena N. Lorenz
EXPERIMENTAL DERMATOLOGY
(2019)
Article
Microbiology
Florian Full, Michiel van Gent, Konstantin M. J. Sparrer, Cindy Chiang, Matthew A. Zurenski, Myriam Scherer, Norbert H. Brockmeyer, Lucie Heinzerling, Michael Sturzl, Klaus Korn, Thomas Stamminger, Armin Ensser, Michaela U. Gack
NATURE MICROBIOLOGY
(2019)
Article
Oncology
Annika Krueckel, Alvaro Moreira, Waltraud Froehlich, Gerold Schuler, Lucie Heinzerling
Article
Oncology
Magid Awadalla, Doll Lauren Alexandra Golden, Syed S. Mahmood, Raza M. Alvi, Nathaniel D. Mercaldo, Malek Z. O. Hassan, Dahlia Banerji, Adam Rokicki, Connor Mulligan, Sean P. T. Murphy, Maeve Jones-O'Connor, Justine V. Cohen, Lucie M. Heinzerling, Merna Armanious, Ryan J. Sullivan, Rongras Damrongwatanasuk, Carol L. Chen, Dipti Gupta, Michael C. Kirchberger, Javid J. Moslehi, Sachin P. Shah, Sarju Ganatra, Paaladinesh Thavendiranathan, Muhammad A. Rizvi, Gagan Sahni, Alexander R. Lyon, Carlo G. Tocchetti, Valentina Mercurio, Franck Thuny, Stephane Ederhy, Michael Mahmoudi, Donald P. Lawrence, John D. Groarke, Anju Nohria, Michael G. Fradley, Kerry L. Reynolds, Tomas G. Neilan
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2019)
Article
Oncology
Titus J. Brinker, Achim Hekler, Alexander H. Enk, Joachim Klode, Axel Hauschild, Carola Berking, Bastian Schilling, Sebastian Haferkamp, Dirk Schadendorf, Stefan Froehling, Jochen S. Utikal, Christof von Kalle, Wiebke Ludwig-Peitsch, Judith Sirokay, Lucie Heinzerling, Magarete Albrecht, Katharina Baratella, Lena Bischof, Eleftheria Chorti, Anna Dith, Christina Drusio, Nina Giese, Emmanouil Gratsias, Klaus Griewank, Sandra Hallasch, Zdenka Hanhart, Saskia Herz, Katja Hohaus, Philipp Jansen, Finja Jockenhoefer, Theodora Kanaki, Sarah Knispel, Katja Leonhard, Anna Martaki, Liliana Matei, Johanna Matull, Alexandra Olischewski, Maximilian Petri, Jan-Malte Placke, Simon Raub, Katrin Salva, Swantje Schlott, Elsa Sody, Nadine Steingrube, Ingo Stoffels, Selma Ugurel, Wiebke Sondermann, Anne Zaremba, Christoffer Gebhardt, Nina Booken, Maria Christolouka, Kristina Buder-Bakhaya, Therezia Bokor-Billmann, Alexander Enk, Patrick Gholam, Holger Haenssle, Martin Salzmann, Sarah Schaefer, Knut Schaekel, Timo Schank, Ann-Sophie Bohne, Sophia Deffaa, Katharina Drerup, Friederike Egberts, Anna-Sophie Erkens, Benjamin Ewald, Sandra Falkvoll, Sascha Gerdes, Viola Harde, Axel Hauschild, Marion Jost, Katja Kosova, Laetitia Messinger, Malte Metzner, Kirsten Morrison, Rogina Motamedi, Anja Pinczker, Anne Rosenthal, Natalie Scheller, Thomas Schwarz, Dora Stoelzl, Federieke Thielking, Elena Tomaschewski, Ulrike Wehkamp, Michael Weichenthal, Oliver Wiedow, Claudia Maria Baer, Sophia Bender-Saebelkampf, Marc Horbruegger, Ante Karoglan, Luise Kraas, Joerg Faulhaber, Cyrill Geraud, Ze Guo, Philipp Koch, Miriam Linke, Nolwenn Maurier, Verena Mueller, Benjamin Thomas, Jochen Sven Utikal, Ali Saeed M. Alamri, Andrea Baczako, Carola Berking, Matthias Betke, Carolin Haas, Daniela Hartmann, Markus V. Heppt, Katharina Kilian, Sebastian Krammer, Natalie Lidia Lapczynski, Sebastian Mastnik, Suzan Nasifoglu, Cristel Ruini, Elke Sattler, Max Schlaak, Hans Wolff, Birgit Achatz, Astrid Bergbreiter, Konstantin Drexler, Monika Ettinger, Sebastian Haferkamp, Anna Halupczok, Marie Hegemann, Verena Dinauer, Maria Maagk, Marion Mickler, Biance Philipp, Anna Wilm, Constanze Wittmann, Anja Gesierich, Valerie Glutsch, Katrin Kahlert, Andreas Kerstan, Bastian Schilling, Philipp Schruefer
EUROPEAN JOURNAL OF CANCER
(2019)